scholarly journals Steady State Kinetic Mechanism of Bruton’s Tyrosine Kinase

2006 ◽  
Vol 20 (4) ◽  
Author(s):  
Marie Dinh ◽  
David Swinney ◽  
James M Bradshaw
2000 ◽  
Vol 352 (3) ◽  
pp. 675-683 ◽  
Author(s):  
Roberto VELASCO-GARCÍA ◽  
Lilian GONZÁLEZ-SEGURA ◽  
Rosario A. MUÑOZ-CLARES

Betaine aldehyde dehydrogenase (BADH) catalyses the irreversible oxidation of betaine aldehyde to glycine betaine with the concomitant reduction of NAD(P)+ to NADP(H). In Pseudomonas aeruginosa this reaction is a compulsory step in the assimilation of carbon and nitrogen when bacteria are growing in choline or choline precursors. The kinetic mechanisms of the NAD+- and NADP+-dependent reactions were examined by steady-state kinetic methods and by dinucleotide binding experiments. The double-reciprocal patterns obtained for initial velocity with NAD(P)+ and for product and dead-end inhibition establish that both mechanisms are steady-state random. However, quantitative analysis of the inhibitions, and comparison with binding data, suggest a preferred route of addition of substrates and release of products in which NAD(P)+ binds first and NAD(P)H leaves last, particularly in the NADP+-dependent reaction. Abortive binding of the dinucleotides, or their analogue ADP, in the betaine aldehyde site was inferred from total substrate inhibition by the dinucleotides, and parabolic inhibition by NADH and ADP. A weak partial uncompetitive substrate inhibition by the aldehyde was observed only in the NADP+-dependent reaction. The kinetics of P. aeruginosa BADH is very similar to that of glucose-6-phosphate dehydrogenase, suggesting that both enzymes fulfil a similar amphibolic metabolic role when the bacteria grow in choline and when they grow in glucose.


2006 ◽  
Vol 188 (3) ◽  
pp. 1155-1158 ◽  
Author(s):  
Sarah H. Lawrence ◽  
James G. Ferry

ABSTRACT Phosphotransacetylase (EC 2.3.1.8) catalyzes the reversible transfer of the acetyl group from acetyl phosphate to coenzyme A (CoA), forming acetyl-CoA and inorganic phosphate. A steady-state kinetic analysis of the phosphotransacetylase from Methanosarcina thermophila indicated that there is a ternary complex kinetic mechanism rather than a ping-pong kinetic mechanism. Additionally, inhibition patterns of products and a nonreactive substrate analog suggested that the substrates bind to the enzyme in a random order. Dynamic light scattering revealed that the enzyme is dimeric in solution.


2001 ◽  
Vol 390 (1) ◽  
pp. 101-108 ◽  
Author(s):  
Jovita Marcinkeviciene ◽  
Wenjun Jiang ◽  
Lisa M Kopcho ◽  
Gregory Locke ◽  
Ying Luo ◽  
...  

2019 ◽  
Vol 85 (2) ◽  
pp. 391-399 ◽  
Author(s):  
Song Mu ◽  
Zhiyu Tang ◽  
William Novotny ◽  
Manal Tawashi ◽  
Ta-Kai Li ◽  
...  

Abstract Purpose Zanubrutinib (BGB-3111) is a potent Bruton’s tyrosine kinase inhibitor with promising clinical activity in B-cell malignancies. Zanubrutinib was shown to be mainly metabolized through cytochrome P450 3A (CYP3A) in vitro. We evaluated the effect of steady-state rifampin (a strong CYP3A inducer) and steady-state itraconazole (a strong CYP3A inhibitor) on the pharmacokinetics (PK), safety, and tolerability of zanubrutinib in healthy Asian and non-Asian subjects. Methods In this open-label, two-part clinical study, 20 participants received a single oral dose of zanubrutinib (320 mg) and oral rifampin (600 mg) in Part A, and 18 participants received a single oral dose of zanubrutinib (20 mg) and oral itraconazole (200 mg) in Part B. Serial blood samples were collected after administration of zanubrutinib alone and zanubrutinib in combination with rifampin or itraconazole for the measurement of PK parameters. Results Coadministration with rifampin decreased AUC0–∞ of zanubrutinib by 13.5-fold and Cmax by 12.6-fold. Coadministration with itraconazole increased the AUC0–∞ of zanubrutinib by 3.8-fold and Cmax by 2.6-fold. The PK of zanubrutinib was consistent between Asian and non-Asian subjects, and  zanubrutinib was well tolerated in this study. Conclusions These results confirm that zanubrutinib is primarily metabolized by CYP3A in humans. The PK of zanubrutinib was comparable between Asian and non-Asian subjects and, therefore, no dose modifications are necessary for zanubrutinib in these ethnic populations.


Biochemistry ◽  
2010 ◽  
Vol 49 (44) ◽  
pp. 9542-9550 ◽  
Author(s):  
Hongling Yuan ◽  
Guoxing Fu ◽  
Phillip T. Brooks ◽  
Irene Weber ◽  
Giovanni Gadda

2006 ◽  
Vol 281 (31) ◽  
pp. 21670-21681 ◽  
Author(s):  
Xinxin Gao ◽  
Thomas K. Harris

Biochemistry ◽  
1995 ◽  
Vol 34 (16) ◽  
pp. 5390-5402 ◽  
Author(s):  
Adil M. Dhalla ◽  
Joseph Yanchunas ◽  
Hsu-Tso Ho ◽  
Paul Falk ◽  
Joseph J. Villafranca ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document